Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | PHASE1 | COMPLETED | 20 | — | — | May 11, 2023 | May 21, 2025 | Jun 15, 2025 | 4 | United States |
The rates of drug-related adverse events will be summarized, and maximum tolerated dose will be determined.
The rates of drug-related adverse events will be summarized, and further evaluated in specific tumor types.
| Arm | Type | Description |
|---|---|---|
| CDX-585 | EXPERIMENTAL | Dose-escalation phase: Eligible patients will receive treatment, based on cohort assigned, in 2-week cycles until progression or intolerance. Expansion phase: Patients enrolled in the expansion phase of the study will receive CDX-585 at the dose level chosen during the escalation phase. |
| Name | Type | Description |
|---|---|---|
| CDX-585 | DRUG | CDX-585 is administered by infusion every 2 weeks |
Key Inclusion Criteria: 1. Recurrent, locally advanced, or metastatic solid tumor cancer excluding primary central nervous system tumors (e.g., glioblastoma). 2. Receipt of standard therapy for the tumor type in the recurrent, locally advanced, or metastatic setting. 3. Measurable (target) disease ...